isoxazoles has been researched along with Astrocytoma, Grade IV in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bindra, RS; Burgenske, DM; Dragojevic, S; Elmquist, WF; Gupta, SK; Kim, M; Mohammad, AS; Sarkaria, JN; Talele, S; Zhang, W | 1 |
| Chen, PF; Chuang, JY; Gean, PW; Ho, KT; Hsueh, YS | 1 |
| Backos, DS; Beall, HD; Campbell, MJ; Duncan, NS; Gajewski, MP; Li, C; Natale, NR; Reigan, P; Rider, KC; Stump, S; Weaver, MJ | 1 |
| Baba, D; Hattori, A; Ichimura, K; Imaoka, T; Itoh, M; Katsumoto, T; Kitabayashi, I; Machida, Y; Matsunaga, H; Nakagawa, M; Nakamura, K; Nishiya, Y; Ogawara, Y; Sampetrean, O; Saya, H; Seki, T; Shima, Y; Suzuki, K; Suzuki, M; Yamagata, K; Yamaguchi, M | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Abdelkafi-Koubaa, Z; Aissa, I; Assel, A; Ben Jannet, H; Chouaïb, K; Harrath, AH; Jalouli, M; Marrakchi, N; Romdhane, A | 1 |
| Becker, N; Djuzenova, CS; Eing, L; Ferreira, FLR; Fiedler, V; Flentje, M; Heiden, R; Katzer, A; Memmel, S; Sauer, M; Sisario, D; Sukhorukov, VL; Zimmermann, H; Zöller, C | 1 |
| Lee, C; Robinson, M; Willerth, SM | 1 |
| Bollavarapu, R; Das, P; Hamme, AT; Hasan, MH; Mitra, D; Raucher, D; Tandon, R; Valente, EJ | 1 |
| Fan, H; Gable, JE; Geier, EG; Giacomini, KM; Irwin, JJ; Sali, A; Schlessinger, A | 1 |
| Chen, LT; Chiang, NJ; Huang, YM; Kao, CA; Wu, SN | 1 |
| Babateen, O; Bhandage, A; Birnir, B; Forsberg Nilsson, K; Jin, Z; Korol, SV; Smits, A; Uhrbom, L; Westermark, B | 1 |
| Deckert, S; Djuzenova, CS; Fiedler, V; Flentje, M; Katzer, A; Michel, K; Sukhorukov, VL; Zimmermann, H | 1 |
| Eccles, SA; Gaspar, N; Gowan, S; Jones, C; Pearson, A; Popov, S; Sharp, SY; Vassal, G; Workman, P | 1 |
| Broekelmann, TJ; Holmes, TC; Izaguirre, EW; Khosla, C; Mecham, R; Rich, KM; Watts, RE; Yuan, L; Zheng, H | 1 |
| Bacher, M; Baron, N; Deuster, O; Dodel, R; Meyer, B; Noelker, C; Schaller, C; Strik, H; Stüer, C | 1 |
| Badn, W; Darabi, A; Eberstål, S; Esbjörnsson, M; Fritzell, S; Siesjö, P; Visse, E | 1 |
| Blassl, C; Djuzenova, CS; Flentje, M; Günther, N; Katzer, A; Kuger, S; Niewidok, N; Polat, B; Roloff, K; Sukhorukov, VL | 1 |
| Biehl, M; Djuzenova, CS; Flentje, M; Günther, N; Hartmann, S; Katzer, A; Krohne, G; Kuger, S; Sukhorukov, VL; Worschech, E; Zimmermann, H | 1 |
| Blumenthal, M; Chen, TC; Kardosh, A; Schönthal, AH; Wang, WJ | 1 |
| Cho, E; Choi, K; Khosla, C; Omary, B; Piper, JL; Rich, KM; Siegel, M; Strnad, P; Yuan, L | 1 |
| Choi, K; Jackson, EN; Khosla, C; Miller, CR; Piwnica-Worms, D; Rich, KM; Siegel, M; Yuan, L | 1 |
| Beattie, BJ; Blasberg, RG; Malkin, MG; Thiessen, B; Vlassenko, AG | 1 |
| Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM | 1 |
| Crowley, J; Eyre, HJ; Hynes, HE; Jaeckle, C; Pollock, TW; Stephens, RL; Taylor, SA | 1 |
1 trial(s) available for isoxazoles and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vidarabine | 1991 |
24 other study(ies) available for isoxazoles and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Brain; Cell Line, Tumor; Female; Glioblastoma; HEK293 Cells; Humans; Infusion Pumps; Isoxazoles; Male; Mice; Mice, Knockout; Mice, Nude; Pyrazines; Xenograft Model Antitumor Assays | 2021 |
A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neurofibromin 1; Receptor, Platelet-Derived Growth Factor alpha; Resorcinols; Tumor Cells, Cultured | 2022 |
10-Alkoxy-anthracenyl-isoxazole analogs have sub-micromolar activity against a Glioblastoma multiforme cell line.
Topics: Alcohols; Cell Line; Cell Line, Tumor; G-Quadruplexes; Glioblastoma; Humans; Isoxazoles | 2022 |
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Humans; Isocitrate Dehydrogenase; Isoxazoles; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Random Allocation; Xenograft Model Antitumor Assays | 2020 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |
Glioblastoma-specific anticancer activity of newly synthetized 3,5-disubstituted isoxazole and 1,4-disubstituted triazole-linked tyrosol conjugates.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Isoxazoles; Molecular Structure; Phenylethyl Alcohol; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2021 |
Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.
Topics: Actin Cytoskeleton; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cytoskeleton; Furans; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Resorcinols; TOR Serine-Threonine Kinases | 2017 |
Direct Reprogramming of Glioblastoma Cells into Neurons Using Small Molecules.
Topics: Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cellular Reprogramming; Cellular Reprogramming Techniques; Colforsin; Diamines; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Homeodomain Proteins; Humans; Isoxazoles; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurons; POU Domain Factors; Pyridines; Pyrimidines; Thiazoles; Thiophenes; Up-Regulation | 2018 |
Design, Synthesis, and Preliminary Studies of Spiro-isoxazoline-peroxides against Human Cytomegalovirus and Glioblastoma ∥.
Topics: Antineoplastic Agents; Antiviral Agents; Brain Neoplasms; Cell Proliferation; Cytomegalovirus; Drug Design; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Isoxazoles; Microbial Sensitivity Tests; Molecular Structure; Peroxides; Spiro Compounds; Tumor Cells, Cultured | 2019 |
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1.
Topics: Amines; Analysis of Variance; Blood-Brain Barrier; Cell Line, Tumor; Crystallography, X-Ray; Cyclohexanecarboxylic Acids; Drug Delivery Systems; Flow Cytometry; Gabapentin; gamma-Aminobutyric Acid; Glioblastoma; HEK293 Cells; Humans; Isoxazoles; Large Neutral Amino Acid-Transporter 1; Leucine; Ligands; Models, Molecular; Tritium | 2013 |
Stimulation of electroporation-induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922.
Topics: Antineoplastic Agents; Calcium; Cell Line, Tumor; Cell Membrane; Electroporation; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Membrane Potentials; Potassium; Resorcinols | 2014 |
Etomidate, propofol and diazepam potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma.
Topics: Anesthetics, General; Cell Line, Tumor; Diazepam; Drug Synergism; Electrophysiological Phenomena; Etomidate; gamma-Aminobutyric Acid; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Ion Channel Gating; Isoxazoles; Propofol; Protein Subunits; Protein Transport; Receptors, GABA-A | 2015 |
Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Administration Schedule; Drug Synergism; Furans; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Female; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Maximum Tolerated Dose; Mice; Mice, Nude; Resorcinols; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Nick-End Labeling; Isoxazoles; Mice; Radiation-Sensitizing Agents; Signal Transduction | 2011 |
Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Targeting; Glioblastoma; Humans; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Receptors, Immunologic; Tumor Cells, Cultured | 2011 |
Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Flow Cytometry; Glioblastoma; Immunohistochemistry; Immunotherapy, Adoptive; Interferon-gamma; Isoxazoles; Male; Neoplasms, Experimental; Rats; Rats, Inbred F344 | 2012 |
Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Topics: Carcinoma; CDC2 Protein Kinase; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase 4; DNA Damage; Glioblastoma; Histones; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Radiation-Sensitizing Agents; Radiation, Ionizing; Resorcinols | 2012 |
Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.
Topics: Blotting, Western; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Flow Cytometry; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Microscopy, Electron, Scanning; Neoplasm Invasiveness; Pyrimidines; Resorcinols; Wound Healing | 2013 |
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glioblastoma; Humans; Indomethacin; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Sulindac | 2004 |
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Carmustine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Glioblastoma; GTP-Binding Proteins; Intestine, Small; Isoxazoles; Mice; Mice, Inbred C3H; Microscopy, Confocal; Protein Glutamine gamma Glutamyltransferase 2; Structure-Activity Relationship; Transglutaminases | 2005 |
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Extracellular Matrix; Female; Fibronectins; Fluorescent Antibody Technique; Glioblastoma; GTP-Binding Proteins; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Survival Rate; Transglutaminases; Tumor Cells, Cultured | 2007 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biological Transport, Active; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Energy Metabolism; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Glioblastoma; Glucose; Humans; Isoxazoles; Leflunomide; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Prognosis; Signal Transduction; Supratentorial Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Division; Cell Survival; Cisplatin; Etoposide; Glioblastoma; Head and Neck Neoplasms; Humans; Isoxazoles; Leflunomide; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |